Hepatitis C Virus Market

Dec 10, 2020

10 likes | 23 Vues

Hepatitis C Virus is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. It is caused by the hepatitis C virus (HCV) and is a major cause of liver cancer. The total prevalent cases of Hepatitis C Virus in the 7MM was 8,257,162 in 2017. The prevalent cases of HCV in the US was 3,251,471. As per the Delveinsight, the therapeutic market of Hepatitis C Virus in the 7MM was found to be USD 10,445 million in 2017, which is expected to increase during the forecast period. The increase in patient awareness (that will lead to an increase in diagnosis rate) and progression of DAA therapies in the form of Pan-genotypic drugs are key drivers for the Hepatitis C Virus market. The key companies in the Hepatitis C Virus market include Cocrystal Pharma, Atea Pharmaceuticals, PRISM Pharma, Ohara Pharmaceuticals, GeneCure Biotechnologies, and others. Source: Hepatitis C Virus Market

DelveInsight

Télécharger la présentation

Hepatitis C Virus Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D